Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

被引：0

作者：

van de Donk, Niels ^{[1
]}

Moreau, Philippe ^{[2
]}

Garfall, Alfred ^{[3
]}

Bhutani, Manisha ^{[4
]}

Oriol, Albert ^{[5
,6
]}

Nooka, Ajay ^{[7
]}

Martin, Thomas ^{[8
]}

Rosinol, Laura ^{[9
]}

Mateos, Maria-Victoria ^{[10
]}

Bahlis, Nizar ^{[11
]}

Popat, Rakesh ^{[12
]}

Besemer, Britta ^{[13
]}

Martinez Lopez, Joaquin ^{[14
]}

Krishnan, Amrita ^{[15
]}

Delforge, Michel ^{[16
]}

Trancucci, Danielle ^{[17
]}

Verona, Raluca ^{[18
]}

Stephenson, Tara ^{[18
]}

Chastain, Katherine ^{[17
]}

Sidana, Surbhi ^{[19
]}

机构：

[1] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[2] Univ Hosp Hotel Dieu, Hematol Clin, Nantes, France

[3] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

[4] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA

[5] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Barcelona, Spain

[6] Hosp Badalona Germans Trias & Pujol, Inst Josep Carreras, Barcelona, Spain

[7] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[8] Univ Calif San Francisco, San Francisco, CA USA

[9] Hosp Clin Barcelona, IDIBAPS, Barcelona, Spain

[10] Univ Hosp Salamanca IBSAL CIC CIBERONC, Salamanca, Spain

[11] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[12] NHS Fdn Trust, Univ Coll London Hosp, London, England

[13] Univ Tubingen, Tubingen, Germany

[14] Hematol Hosp 12 Octubre, Madrid, Spain

[15] City Hope Comprehens Canc Ctr, Duarte, CA USA

[16] Univ Leuven, Leuven, Belgium

[17] Janssen Res & Dev, Raritan, NJ USA

[18] Janssen Res & Dev, Spring House, PA USA

[19] Stanford Univ, Sch Med, Stanford, CA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

relapsed/refractory multiple myeloma; bispecifics; multiple myeloma; phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-163

引用

页码：S477 / S478

页数：2

共 50 条

[31] A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody).
Rodriguez-Otero, Paula
D'Souza, Anita
Reece, Donna Ellen
van de Donk, Niels W. C. J.
Chari, Ajai
Krishnan, Amrita Y.
Martin, Thomas G.
Mateos, Maria-Victoria
Morillo, Daniel
Hurd, David Duane
Rosinol, Laura
Balari, Anna Sureda
Wasch, Ralph
Vishwamitra, Deeksha
Lin, Shun Xin Wang
Prior, Thomas
Vandenberk, Lien
Smit, Marie-Anne Damiette
Rocafiguera, Albert Oriol
Dholaria, Bhagirathbhai R.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[32] REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Madduri, Deepu
Rosko, Ashley
Brayer, Jason
Zonder, Jeffrey
Bensinger, William I.
Li, Jingjin
Xu, Linzhi
Adriaens, Lieve
Chokshi, Dhruti
Zhang, Weijiang
Boyapati, Anita
Sharma, Manish
Seebach, Frank
Sirulnik, L. Andres
Weinreich, David M.
Yancopoulos, George D.
Dhodapkar, Madhav V.
Lentzsch, Suzanne
Cooper, Dennis
Jagannath, Sundar
BLOOD, 2020, 136
[33] Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)
van de Donk, Niels W. C. J.
Garfall, Alfred L.
Benboubker, Lotfi
Uttervall, Katarina
Groen, Kaz
Rosinol, Laura
Matous, Jeffrey V.
Vishwamitra, Deeksha
Hodin, Caroline
Stephenson, Tara
Qi, Keqin
Zuppa, Athena
Chastain, Katherine
Mateos, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S549 - S549
[34] Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.
Sun, Mingyuan
Qiu, Lugui
Wei, Yongqiang
Jin, Jie
Li, Xin
Liu, Xue
Yin, Shaohong
Qi, Junyuan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[35] Longer-Term Follow-Up of Patients Receiving Prophylactic Tocilizumab for Cytokine Release Syndrome in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma
Rosinol, Laura
Garfall, Alfred
Benboubker, Lotfi
Uttervall, Katarina
Groen, Kaz
van de Donk, Niels
Matous, Jeffrey
Vishwamitra, Deeksha
Hodin, Caroline
Stephenson, Tara
Qi, Keqin
Zuppa, Athena
Chastain, Katherine
Mateos Manteca, Maria-Victoria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S84 - S85
[36] Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Jin, Chunxiang
Chen, Rongrong
Fu, Shan
Zhang, Mingming
Teng, Yuanyin
Yang, Tingting
Song, Fengmei
Feng, Jingjing
Hong, Ruimin
Cui, Jiazhen
Huang, Simao
Xu, Huijun
Zhang, Yanlei
Wei, Guoqing
Cai, Zhen
Kwong, Yok-Lam
Chan, Thomas Sau Yan
Chang, Alex H.
Huang, He
Hu, Yongxian
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (03)
[37] Longer-term follow-up of patients (pts) receiving prophylactic tocilizumab (toci) for the reduction of cytokine release syndrome (CRS) in the phase 1/2 MajesTEC-1 study of teclistamab in relapsed/refractory multiple myeloma (RRMM).
van de Donk, Niels W. C. J.
Garfall, Alfred L.
Benboubker, Lotfi
Uttervall, Katarina
Groen, Kaz
Rosinol, Laura
Matous, Jeffrey V.
Vishwamitra, Deeksha
Hodin, Caroline
Stephenson, Tara
Qi, Keqin
Zuppa, Athena
Chastain, Katherine
Mateos, Maria-Victoria
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[38] Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
Lesokhin, Alexander M.
Arnulf, Bertrand
Niesvizky, Ruben
Mohty, Mohamad
Bahlis, Nizar J.
Tomasson, Michael H.
Rodriguez-Otero, Paula
Quach, Hang
Raje, Noopur S.
Iida, Shinsuke
Raab, Marc-Steffen
Czibere, Akos
Sullivan, Sharon
Leip, Eric
Viqueira, Andrea
Leleu, Xavier
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[39] MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)
Levy, Moshe
Bahlis, Nizar
Raje, Noopur
Costello, Caitlin
Dholaria, Bhagirathbhai
Solh, Melhem
Tomasson, Michael
Dube, Harman
Damore, Michael
Lon, Hoi Kei
Basu, Cynthia
Skoura, Athanasia
Chan, Edward
Trudel, Suzanne
Jakubowiak, Andrzej
Chu, Michael
Gasparetto, Cristina
Dalovisio, Andrew
Sebag, Michael
Lesokhin, Alexander
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S439 - S439
[40] A Phase 1/2 study of teclistamab, a humanized BCMA x CD3 bispecific Ab in Japanese patients with relapsed/refractory MM
Ishida, Tadao
Kuroda, Yoshiaki
Matsue, Kosei
Komeno, Takuya
Ishiguro, Takuro
Ishikawa, Jun
Ito, Toshiro
Kosugi, Hiroshi
Sunami, Kazutaka
Nishikawa, Kazuko
Shibayama, Kazuhiro
Aida, Kensuke
Yamazaki, Hiroshi
Inagaki, Mitsuo
Kobayashi, Hisanori
Iida, Shinsuke
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2025, 121 (02) : 222 - 231

← 1 2 3 4 5 →